Research GradeWeight Management & Metabolic

Tirzepatide

10 mg

Dual GIP/GLP-1 receptor agonist for metabolic research.

Overview

Tirzepatide is a dual GIP and GLP-1 receptor agonist developed for the study of glucose-dependent insulin secretion and weight regulation pathways.

Mechanism of Action

Tirzepatide engages GIP and GLP-1 receptors on pancreatic β-cells, potentiating glucose-stimulated insulin release while modulating glucagon secretion. Central GLP-1R activation in hindbrain nuclei contributes to satiety signaling.

Research Findings

Tirzepatide Once Weekly for the Treatment of Obesity

NEJM, 2022 (PMID: 35658024)

SURMOUNT-1 trial outcomes.

Potential Research Applications

Incretin research
Glycemic regulation studies
Adiposity models

Often researched with

Retatrutide

10 mg

Triple receptor agonist (GLP-1 / GIP / glucagon) under investigation for metabolic research.

Semaglutide

5 mg

Long-acting GLP-1 receptor agonist for glycemic research.

Growth Stack

CJC-1295 2 mg + Ipamorelin 2 mg

GHRH + GHRP combination for somatotropic research.